SCLC Staging and Screening: Limited- vs Extensive-Stage Disease

Welcome back to another AJMC Peer Exchange series. In "SCLC Staging and Screening: Limited- vs Extensive-Stage Disease," moderator Ryan Haumschild, PharmD, MS, MBA, CPEL is joined by Mohit Narang, MD, Millie Das, MD, Dave Jackman, MD, and Wade Iams, MD to open the series by framing how small cell lung cancer is staged, diagnosed, and screened for.

The discussion opens with a foundational question: how does limited-stage small cell lung cancer differ from extensive-stage disease in terms of staging, prognosis, and treatment intent? Historically, clinicians defined limited-stage disease by whether the tumor could be encompassed within a single, feasible radiation field, since chemoradiotherapy was long considered the only potentially curative option for local and regional disease. Extensive-stage disease, by contrast, has traditionally been treated with systemic therapy aimed at extending survival and preserving quality of life rather than achieving cure, though the panel notes that a small but growing group of extensive-stage patients now become long-term survivors as treatment has advanced.

The conversation turns to how these two populations break down in practice. Roughly 30% of patients present with limited-stage disease, while about 70% present with extensive-stage, metastatic disease at diagnosis, reflecting how aggressively and rapidly small cell lung cancer typically progresses. Many limited-stage cases are found incidentally, often when a current or former smoker undergoes imaging for an unrelated concern, such as a cardiovascular workup, and a lung mass is discovered along the way. The panel credits expanding, though still incomplete, national lung cancer screening programs with identifying more cases at the limited stage, where cure remains a realistic goal.

The episode closes on a note of cautious optimism. While the majority of patients still present with extensive-stage disease, recent treatment advances are already helping more of these patients live longer and with a better quality of life than in years past. The panel agrees that continued investment in screening, paired with earlier identification of high-risk current and former smokers, could meaningfully shift more diagnoses toward the limited-stage population, where treatment intent remains curative and where the field's recent progress has been most dramatic.

The next episode in this series, "Limited-Stage SCLC: Chemoradiotherapy Standards and Scheduling Decisions," turns to the chemoradiotherapy regimens and scheduling choices that define limited-stage treatment today.